Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Gilead Sciences Inc., liquidity ratios (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Current ratio 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Quick ratio 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Cash ratio 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Gilead Sciences Inc. current ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Gilead Sciences Inc. quick ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Gilead Sciences Inc. cash ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.

Current Ratio

Gilead Sciences Inc., current ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Current assets 12,317 14,041 16,085 15,980 14,287 13,456 14,443 13,554 13,175 12,629 14,772 13,991 13,925 13,278 15,996 30,926 24,643 26,950 30,296 28,361 33,727 34,024
Current liabilities 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423 9,220 8,558 11,610 10,245 10,214 9,705 11,397 9,509 10,564 8,879 9,759 9,567 8,961 9,397
Liquidity Ratio
Current ratio1 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14 3.18 1.15 0.89 1.04
Amgen Inc. 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Bristol-Myers Squibb Co. 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66 1.60 3.83 3.88 1.93
Danaher Corp. 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32 5.19 3.43 2.32 2.18
Eli Lilly & Co. 1.11 1.35 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11 1.16 1.17 1.13 1.12
Johnson & Johnson 1.07 1.17 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31 1.26 1.26 1.33 1.44
Merck & Co. Inc. 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11 1.24 1.26 1.21 1.37
Moderna Inc. 4.09 4.03 3.42 2.46 3.39 3.46 2.73 2.10 1.99 1.77 1.76 1.35 1.24 1.39 1.43 2.43 17.30 9.29 7.89 7.40 6.77 7.17
Pfizer Inc. 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03 0.88 0.90 1.47 1.54
Regeneron Pharmaceuticals Inc. 5.44 5.27 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21 3.67 4.03 3.88 4.58
Thermo Fisher Scientific Inc. 1.72 1.70 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32 1.92 1.80 1.49 1.69

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 12,317 ÷ 10,781 = 1.14

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Gilead Sciences Inc. current ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.

Quick Ratio

Gilead Sciences Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,772 4,718 6,085 5,705 5,704 4,936 5,412 4,699 4,739 4,296 5,338 4,362 4,893 4,065 5,997 12,886 6,746 10,051 11,631 9,474 11,240 16,927
Short-term marketable debt securities 1,179 1,159 963 936 973 961 924 1,029 1,182 1,376 1,632 1,601 1,411 11,089 12,168 10,734 12,721 13,382 15,943 10,977
Accounts receivable, net 4,663 4,669 4,660 4,790 4,229 4,162 4,777 4,354 4,118 3,787 4,493 4,566 4,149 3,925 4,892 3,913 3,194 3,907 3,582 3,315 3,396 3,283
Total quick assets 7,435 9,387 11,924 11,654 10,896 10,034 11,162 10,014 9,781 9,112 11,013 10,304 10,674 9,591 12,300 27,888 22,108 24,692 27,934 26,171 30,579 31,187
 
Current liabilities 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423 9,220 8,558 11,610 10,245 10,214 9,705 11,397 9,509 10,564 8,879 9,759 9,567 8,961 9,397
Liquidity Ratio
Quick ratio1 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88 2.91 0.92 0.64 0.78
Amgen Inc. 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Bristol-Myers Squibb Co. 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38 1.26 3.63 3.61 1.64
Danaher Corp. 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92 4.68 2.99 1.78 1.58
Eli Lilly & Co. 0.61 0.68 0.52 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64 0.68 0.66 0.67 0.65
Johnson & Johnson 0.77 0.84 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98 0.94 0.93 0.95 1.01
Merck & Co. Inc. 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66 0.78 0.80 0.75 0.88
Moderna Inc. 3.66 3.64 3.15 2.15 2.78 2.87 2.29 1.62 1.55 1.44 1.52 1.21 1.13 1.30 1.37 2.35 17.01 9.10 7.74 7.22 6.64 7.01
Pfizer Inc. 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60 0.50 0.50 0.71 0.72
Regeneron Pharmaceuticals Inc. 4.43 4.40 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38 2.81 3.14 2.99 3.66
Thermo Fisher Scientific Inc. 1.24 1.19 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48 1.19 0.97 0.85 0.89

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 7,435 ÷ 10,781 = 0.69

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Gilead Sciences Inc. quick ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.

Cash Ratio

Gilead Sciences Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,772 4,718 6,085 5,705 5,704 4,936 5,412 4,699 4,739 4,296 5,338 4,362 4,893 4,065 5,997 12,886 6,746 10,051 11,631 9,474 11,240 16,927
Short-term marketable debt securities 1,179 1,159 963 936 973 961 924 1,029 1,182 1,376 1,632 1,601 1,411 11,089 12,168 10,734 12,721 13,382 15,943 10,977
Total cash assets 2,772 4,718 7,264 6,864 6,667 5,872 6,385 5,660 5,663 5,325 6,520 5,738 6,525 5,666 7,408 23,975 18,914 20,785 24,352 22,856 27,183 27,904
 
Current liabilities 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423 9,220 8,558 11,610 10,245 10,214 9,705 11,397 9,509 10,564 8,879 9,759 9,567 8,961 9,397
Liquidity Ratio
Cash ratio1 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.31 0.44 0.34 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50 2.56 0.61 0.32 0.38
Amgen Inc. 0.43 0.49 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07
Bristol-Myers Squibb Co. 0.29 0.37 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95 0.84 3.10 3.02 0.99
Danaher Corp. 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52 4.04 2.40 1.08 0.84
Eli Lilly & Co. 0.12 0.14 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14 0.21 0.15 0.20 0.19
Johnson & Johnson 0.47 0.54 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54 0.54 0.51 0.49 0.53
Merck & Co. Inc. 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32 0.47 0.39 0.35 0.47
Moderna Inc. 3.59 3.58 2.85 1.73 2.71 2.55 2.01 1.23 1.16 1.09 1.18 0.89 0.90 0.92 1.05 2.22 16.81 9.05 7.71 7.16 6.61 6.97
Pfizer Inc. 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31 0.26 0.25 0.40 0.39
Regeneron Pharmaceuticals Inc. 2.80 2.94 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14
Thermo Fisher Scientific Inc. 0.60 0.52 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54 0.39 0.22 0.30 0.19

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,772 ÷ 10,781 = 0.26

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Gilead Sciences Inc. cash ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.